SOHO 2023 | Richter’s transformation: the need for more therapeutic agents in this space
Tanya Siddiqi, MD, City of Hope, Duarte, CA, provides an overview of treatment options available for patients with Richter’s transformation (RT), highlighting the lack of efficacious therapies in this disease setting. Dr Siddiqi talks on several agents being explored in clinical trials, including lisocabtagene maraleucel (liso-cel) in combination with nivolumab and ibrutinib, and bispecific antibodies. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
We really don’t have a lot of good treatment options for Richter’s right now. Unfortunately, nothing that works consistently. So historically we’ve used anthracycline-based chemotherapy, doesn’t really work very well or for long. We’re trying to combine it with things like venetoclax and whatnot. The trials going on with that frontline treatment for Richter’s...
We really don’t have a lot of good treatment options for Richter’s right now. Unfortunately, nothing that works consistently. So historically we’ve used anthracycline-based chemotherapy, doesn’t really work very well or for long. We’re trying to combine it with things like venetoclax and whatnot. The trials going on with that frontline treatment for Richter’s. I have a trial for relapsed Richter’s with CAR-T cells, liso-cel again in combination with nivolumab and ibrutinib to see if we can sort of tackle the lymphoma from several different fronts at the same time. And so people are trying many different things, bispecifics and other novel agents and combinations. We don’t have a good answer for Richter’s right now. The way I treat patients, we try to get them into a remission and take them to transplant, because an allo-transplant, you can still have up to 60% chance of cure, knowing they’ll have graft-versus-host disease and infection risks and whatnot, but at least you might cure them. So it’s a tough, tough setting. We need to learn more.
Read more...
